Lilly's oral weight-loss pill shows promise amid pharma shakeup: TIME
In a detailed feature by TIME Magazine, pharmaceutical giant Eli Lilly has unveiled promising early results from clinical trials of its experimental oral drug orforglipron, a GLP-1-based treatment for diabetes and weight loss. The development marks a potentially transformative moment for both the company and the obesity-treatment landscape.
The data, presented during a critical meeting at Lilly's Indianapolis headquarters on April 15, showed that orforglipron lowered blood sugar levels and aided weight loss without serious side effects like liver toxicity—an issue that recently led Pfizer to abandon its own oral drug in the same category. Orforglipron's results were comparable to Lilly's injectable blockbuster tirzepatide (Mounjaro).
If approved by the FDA, orforglipron could become the first oral GLP-1 drug for weight loss on the market. Unlike competing drugs, it requires no dietary restrictions or timing constraints and is easier and cheaper to manufacture and distribute—especially in areas where injectables are impractical.
Lilly's CEO David Ricks and Chief Scientific Officer Dr Dan Skovronsky credited the company's agile approach, culture shift, and high-speed innovation for the drug's progress. The pill was licensed from Japan's Chugai in 2018 and developed 30–40% faster than industry averages, according to Ricks.
The company is investing heavily in domestic production, anticipating a surge in demand. Trials are ongoing to evaluate orforglipron's effectiveness in non-diabetic obesity and other conditions like hypertension. If successful, the drug could dramatically expand access to obesity treatments and redefine the market.
This effort is part of Lilly's broader push to break industry norms, including direct-to-consumer models like Lilly Direct, which bypass intermediaries to lower costs. With additional breakthroughs like the Alzheimer's drug Kisunla, Lilly is now the world's most valuable pharma firm—and possibly the first on track to a $1 trillion valuation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
8 hours ago
- Business Recorder
Lilly launches Mounjaro pen in India at $160 for starting dose, stepping up Novo rivalry
Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees (nearly $160) for its starting dose of 2.5 mg in India, stepping up competition with Novo Nordisk. Lilly said in June it received approval from India's drug regulator for its once-weekly Mounjaro Kwikpen, two days after Novo Nordisk launched Wegovy in multiple dose strengths in a similar pen device. Mounjaro Kwikpen is available in six dose strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — with pricing calculated for a month's supply. The smallest two doses are priced at 14,000 and 17,500 rupees, respectively, and the 7.5 mg and 10 mg doses cost 22,000 rupees. The 12.5 mg and 15 mg doses cost 27,500 rupees, the company said. 'If we look at how the highest doses of Mounjaro and Wegovy are priced, it appears (that) Mounjaro's pricing is attractive and competitive,' said Vishal Manchanda from Systematix Institutional Equities. Wegovy's smallest doses of 0.25 mg, 0.5 mg and 1 mg cost 17,345 rupees a month, and its highest doses of 1.7 mg and 2.4 mg cost 24,280 rupees and 26,015 rupees a month, respectively. Lilly began selling Mounjaro in India in late March for diabetes and obesity in 2.5 mg and 5 mg vials. Both drugs have seen strong demand since then, with sales in July doubling month-on-month. The drugs belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.
Business Recorder
17-06-2025
- Business Recorder
Eli Lilly strikes $1.3bn deal to buy gene-editing biotech Verve Therapeutics, companies say
Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, sending Verve's shares up 77.7% in premarket trading. Lilly has struck multiple partnership deals with gene-editing companies in the last two years to expand its portfolio beyond its blockbuster weight-loss and diabetes drugs. The drugmaker will buy Verve for $10.5 per share, which is a premium of 67.5% on the company's last close. The deal includes an upfront payment of almost $1 billion and a further $300 million based on the genetic-medicines firm achieving certain clinical milestones. The companies are already partnering to develop gene-editing therapies to reduce high cholesterol in people with heart disease, which are expected to be used in combination with other drugs. Shares of Lilly were down 1% before the bell. Verve's gene-editing medicines target the PCSK9, ANGPTL3 and LPA genes responsible for regulating blood cholesterol levels.
Express Tribune
05-06-2025
- Express Tribune
Weight-loss drugs like Ozempic, Wegovy, and Mounjaro may lower oral contraceptive effectiveness., UK's MHRA warns
Listen to article The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has issued an alert urging women using weight-loss medications such as Ozempic, Wegovy, and Mounjaro to use effective contraception after receiving multiple reports of pregnancies among users, The Guardian reported on June 5, 2025. The alert follows 40 reports of pregnancy in women taking these weight-loss drugs, prompting the MHRA to warn that Mounjaro, in particular, may reduce the effectiveness of oral contraceptives. The agency advises that women taking this drug use barrier contraception, such as condoms, in addition to oral contraceptives, according to The Guardian. The MHRA received 26 pregnancy-related reports concerning Mounjaro and an additional eight reports linked to semaglutide-based drugs (Ozempic and Wegovy). Another weight-loss medication, Saxenda, which contains liraglutide, also garnered nine reports. Read more: Ozempic shows promise in reversing liver disease, research finds While it's unclear whether the pregnancies were unintended, some women confirmed their pregnancies were unplanned, as reported by The Guardian. The MHRA has emphasised that these medications should not be used during pregnancy or while trying to conceive due to insufficient safety data regarding potential harm to a developing baby. Women taking these drugs are also advised to continue contraception for up to two months after stopping the medication before attempting to become pregnant, as noted by the health agency. Also read: Popular weight loss drug Ozempic linked to higher risk of blindness Dr. Channa Jayasena, a consultant in reproductive endocrinology, noted that GLP-1 medications like Ozempic and Wegovy are effective in aiding weight loss but could increase fertility in women with obesity by enhancing fertility. However, these drugs may also interfere with the absorption of oral contraceptives, potentially increasing the risk of unintended pregnancies. This was also highlighted in The Guardian's coverage. Read: Ozempic-fueled weight loss takes over Oscars 2025 as Hollywood's size zero trend returns Dr. Alison Cave, the MHRA's chief safety officer, urged patients not to misuse these medications for weight loss, stressing that they are licensed for specific medical conditions and not for cosmetic purposes. She further recommended that patients read the provided patient information leaflets and consult healthcare professionals before using these powerful treatments, as reported in The Guardian.
